A panel of advisors of the Food and Drug Administration on Tuesday (Oct 31) held a day-long meeting grappling with potential risks posed by a novel therapy for sickle cell disease, a rare blood disorder that affects a significant population globally.

FDA weighs risks and benefits of CRISPR therapy for sickle cell disease

sickle-cell-disease

Sickle Cell Disease, News on Sickle Cell Disease, stories on Sickle Cell Disease, articles on Sickle Cell Disease, Sickle Cell Disease stories at Wion, Sickle Cell Disease news, Sickle Cell Disease latest news

sickle cell-disease

FDA weighs risks and benefits of CRISPR therapy for sickle cell disease